英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
45242查看　45242　在百度字典中的解释百度英翻中〔查看〕
45242查看　45242　在Google字典中的解释Google英翻中〔查看〕
45242查看　45242　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • AnaptysBio
    AnaptysBio, Inc (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today reported financial results for the first quarter ended March 31, 2026, and provided a business update
  • Investor Relations | AnaptysBio, Inc.
    The Investor Relations website contains information about AnaptysBio, Inc 's business for stockholders, potential investors, and financial analysts
  • Key Catalysts - Anaptys Royalty Co
    Significant upcoming catalysts expected within the next two years 1 Not-exhaustive; 2 Registrational studies also ongoing in China and Japan; 3 HSNCC - Head and neck squamous cell carcinomas; 4 Per clinicaltrials gov estimated primary completion date; 5 GSK Q4 2025 earnings
  • Anaptys Announces Positive Top-Line Phase 3 Clinical . . . - AnaptysBio, Inc.
    SAN DIEGO, Oct 09, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced positive top-line results from its global Phase 3 GEMINI-1 trial evaluating the safety and efficacy of imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP) flares Investigational
  • Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or . . .
    SAN DIEGO, Nov 10, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that investigational rosnilimab was safe and well tolerated but did not meet the primary endpoint of mean change from baseline in modified Mayo Score (mMS) or key secondary endpoints of clinical response
  • Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not . . .
    SAN DIEGO, Dec 11, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the global, 201-patient ARISE
  • Daniel Faga - Anaptys Royalty Co
    AnaptysBio now exclusively manages the financial collaborations relating to Jemperli with GSK and imsidolimab with Vanda Effective April 20, 2026, Anaptys has spun off its biopharma business, including its therapies, into a new company, First Tracks Biotherapeutics
  • Anaptys Announces First Quarter 2026 Financial Results and Provides . . .
    SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today reported financial results for the first quarter ended March 31, 2026, and provided a business update
  • Anaptys Announces Participation at Upcoming Investor Conferences
    SAN DIEGO, Feb 05, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: Guggenheim





中文字典-英文字典  2005-2009